Home > Cardiology > ESC 2021 > Dapagliflozin reduces incidence of sudden death in HFrEF patients

Dapagliflozin reduces incidence of sudden death in HFrEF patients

Presented By
Dr James Curtain, University of Glasgow, Scotland
Conference
ESC 2021
Trial
DAPA-HF
A novel analysis of DAPA-HF investigated the efficacy of dapagliflozin on ventricular arrhythmia (VA), resuscitated cardiac arrest (RCA), and sudden death. The results showed a significantly reduced likelihood for the composite outcome by 21% [1]. The DAPA-HF (NCT03036124) trial evaluated dapagliflozin’s efficacy to prevent adverse outcomes of heart failure (HF) in patients with HF and reduced ejection fraction (HFrEF). The main results showed a 26% risk reduction of the composite primary endpoint of cardiovascular (CV) death or worsening of HF. DAPA-HF included 4,744 patients with a left ventricular ejection fraction (LVEF) ≤40% and an NT-proBNP ≥600pg/mL who were in NYHA class 2–4. The mean age was 67 years, mean LVEF 31%, 45% suffered from diabetes, and 41% from chronic kidney disease. The primary outcome of this new analysis co...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on